Parc: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults

Nicola Fenwick, Rebekah Weston, Keith Wheatley, Jodie Hodgson, Lynley Marshall, Martin Elliott, Guy Makin, Antony Ng, Bernadette Brennan, Stephen Lowis, Jenny Adamski, John Paul Kilday, Rachel Cox, Mike Gattens, Andrew Moore, Toby Trahair, Milind Ronghe, Martin Campbell, Helen Campbell, Molly W WilliamsMaria Kirby, Natasha Van Eijkelenburg, Jennifer Keely, Ugo Scarpa, Victoria Stavrou, Livingstone Fultang, Sarah Booth, Paul Cheng, Carmela De Santo, Francis Mussai

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Parc: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science